Karen Andersen

• Optimal Opportunities

  By Ed McCarthy, CFP  |  February 22, 2013

  While Actavis (ACT) narrowed its 2013 guidance expectations in the wake of an unexpected Concerta approval, the company is still poised to post close to 30% EPS growth and potentially double-digit annual EPS growth through 2016.

• 

  Obamacare Here to Stay Even With GOP Victory, Analysts Say

  By Gil Weinreich, AdvisorOne  |  October 26, 2012

  Regardless of which party claims the greatest victory in November elections, Obamacare is likely to remain in place while the outcome of budget sequestration will be the key catalyst for the entire sector, Morningstar analysts say.

• Core Competency

  August 23, 2012

  Solid growth and promising research and development pipelines bode well for companies that sell pharmaceutical and related health-care products.

• Growth Checkup

  February 24, 2012

• Health Care/Biotech: A Good Prognosis

  By Ed McCarthy, CFP  |  September 1, 2011

  Companies offering advanced medical technology and pharmaceuticals continue to show strong revenue and profit growth.

• Health Care: A Fit Forecast

  By Ed McCarthy, CFP  |  March 1, 2011

• Health Care: Potent Pipelines

  By Janet Levaux, AdvisorOne  |  March 1, 2010

  Damien Conover, CFA Karen Andersen, CFA Morningstar 312-696-6000 Pharmaceuticals: While the majority of pharmaceutical companies are losing patents on major blockbuster drugs over the next five years, strong pipelines...

• The Right Remedies

  By Janet Levaux, AdvisorOne  |  September 1, 2009

  Research's Health Care Guide: Beckman Coulter Inc. (BEC) Roche Holding AG (RHHBY) Watson Pharmaceuticals Inc. (WPI) --- Karen Andersen,...